Spots Global Cancer Trial Database for aml, adult
Every month we try and update this database with for aml, adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03194685 | AML, Adult | FF-10101-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03194685 | AML, Adult | FF-10101-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | NCT04079738 | AML AML, Adult | TAK-659 Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | NCT05736965 | AML, Adult | Selinexor Azacitidine Venetoclax | 18 Years - | Shanghai Tong Ren Hospital | |
| OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia | NCT06377579 | AML, Adult | 18 Years - | French Innovative Leukemia Organisation | ||
| A Study of Chidamide With AZA in MRD Positive AML After Transplant | NCT06066905 | AML, Adult Minimal Residua... | chidamide and a... | 18 Years - | Guangdong Provincial People's Hospital | |
| Quality of Life Model for Older Patients With AML | NCT04380441 | AML, Adult Acute Myeloid L... | 60 Years - | H. Lee Moffitt Cancer Center and Research Institute | ||
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | NCT04079738 | AML AML, Adult | TAK-659 Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | NCT04482894 | Leukemia, Acute AML, Adult ALL, Adult Myelodysplastic... | Palliative Care... | 18 Years - | University of Virginia | |
| Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | NCT04128020 | Aml AML, Adult | Nivolumab Azacitidine | 18 Years - | Big Ten Cancer Research Consortium | |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | NCT03884829 | AML, Adult Myelodysplastic... ALL, Adult CML, Refractory CLL, Refractory | CYC140 | 18 Years - | Cyclacel Pharmaceuticals, Inc. | |
| EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 | NCT03612739 | AML, Adult Myelodysplastic... | NKR-2 CAR-T Cel... | 18 Years - | Celyad Oncology SA | |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | NCT04079738 | AML AML, Adult | TAK-659 Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | NCT05947344 | AML, Adult | STI-8591 | 18 Years - | Zhejiang ACEA Pharmaceutical Co. Ltd. | |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | NCT04482894 | Leukemia, Acute AML, Adult ALL, Adult Myelodysplastic... | Palliative Care... | 18 Years - | University of Virginia | |
| A Study of BN104 in the Treatment of Acute Leukemia | NCT06052813 | ALL, Adult AML, Adult | BN104 | 18 Years - | BioNova Pharmaceuticals (Shanghai) LTD. | |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | NCT03884829 | AML, Adult Myelodysplastic... ALL, Adult CML, Refractory CLL, Refractory | CYC140 | 18 Years - | Cyclacel Pharmaceuticals, Inc. | |
| OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia | NCT06377579 | AML, Adult | 18 Years - | French Innovative Leukemia Organisation | ||
| Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | NCT05665075 | AML, Adult | QN-023a Cyclophosphamid Fludarabine Cytarabine VP-16 | 18 Years - | Zhejiang University | |
| Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | NCT05601466 | AML, Adult | QN-023a Cyclophosphamid Fludarabine Cytarabine | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | NCT05947344 | AML, Adult | STI-8591 | 18 Years - | Zhejiang ACEA Pharmaceutical Co. Ltd. | |
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | NCT04755244 | Acute Myeloid L... AML, Adult | evorpacept venetoclax azacitidine | 18 Years - | ALX Oncology Inc. | |
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | NCT05736965 | AML, Adult | Selinexor Azacitidine Venetoclax | 18 Years - | Shanghai Tong Ren Hospital | |
| Quality of Life Model for Older Patients With AML | NCT04380441 | AML, Adult Acute Myeloid L... | 60 Years - | H. Lee Moffitt Cancer Center and Research Institute | ||
| D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia | NCT06188182 | AML, Adult | 18 Years - 70 Years | Assiut University | ||
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | NCT04755244 | Acute Myeloid L... AML, Adult | evorpacept venetoclax azacitidine | 18 Years - | ALX Oncology Inc. | |
| Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | NCT05665075 | AML, Adult | QN-023a Cyclophosphamid Fludarabine Cytarabine VP-16 | 18 Years - | Zhejiang University | |
| EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 | NCT03612739 | AML, Adult Myelodysplastic... | NKR-2 CAR-T Cel... | 18 Years - | Celyad Oncology SA | |
| Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | NCT04512105 | Acute Myeloid L... Chronic Lymphoc... AML, Adult CLL CLL, Relapsed CLL, Refractory | Pitavastatin Venetoclax | 18 Years - | University of California, Irvine | |
| Revumenib in Combination With 7+3 + Midostaurin in AML | NCT06313437 | Acute Myeloid L... AML, Adult AML With Gene M... AML Leukemia | Revumenib Midostaurin Cytarabine Daunorubicin | 18 Years - 75 Years | Dana-Farber Cancer Institute | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia | NCT02986620 | AML, Adult | IDH mutation te... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study of Chidamide With AZA in MRD Positive AML After Transplant | NCT06066905 | AML, Adult Minimal Residua... | chidamide and a... | 18 Years - | Guangdong Provincial People's Hospital | |
| A Study of BN104 in the Treatment of Acute Leukemia | NCT06052813 | ALL, Adult AML, Adult | BN104 | 18 Years - | BioNova Pharmaceuticals (Shanghai) LTD. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
